| *together with Option Pit & Brownstone Research | Good day, 360! | Here are some of our top movers today. And don't forget to join us in Market Masters - b/c if you missed Jeff William's Weekly Wiretap on IWM, you NEED to tune in for all the action (right now name your own price to get his next pick Monday)! Insane deal!!! | | FOCUS LISTπ | INM - Up over 80% in the pre-market after reporting INM-901 significantly reduces neuroinflammation in Alzheimer's disease ex vivo study | IBIO - Up over 48% in pre after unveiling obesity program with AstralBio for novel Amylin agonist antibody demonstrating promising in vivo results | NA - Up over 170% in pre after announcing US$500 million convertible notes private placement for BNB treasury strategy | | *together with Option Pit | Updated Track Record (May/June) from Olivia Voz: |  | *Max potential of Olivia's Game Plan picks as reported by Option Pit. Does not represent her personal gain unless noted. Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| 53%...78%...80%. | We'd Say Olivia's Strategy Is Worth Learning! | Masterclass With Jeff Bishop Happening Soon. | >> Exclusive Details Right Here << |
|
| | HOTLISTπ₯ | INM - Up over 80% in the pre-market after reporting INM-901 significantly reduces neuroinflammation in Alzheimer's disease ex vivo study | InMed Pharmaceuticals Inc. (INM) is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs. | In the pre-market this morning, the company announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease. | Highlights include: | Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1Ξ², IL-2, and KC/Gro | Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration | Reduces key pro-inflammatory markers, independent of amyloid beta or tau pathology | Share of INM traded up over 80% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $5.35. Beyond that, $7, $8, $9.10 and $10 come into play. | Below $5.35, targets to the downside are $5, $4.50, $4, $3.80, $3 and then a gap fill at $2.45. | | IBIO - Up over 48% in pre after unveiling obesity program with AstralBio for novel Amylin agonist antibody demonstrating promising in vivo result | iBio, Inc. (IBIO) is an AI-driven innovator of next-generation antibody therapies. In the pre-market this morning, the company announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60% (p<0.05), equivalent to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide (67%). | The effect on food intake was monitored over various time points in this side-by-side study with the amylin agonist iBio discovered and a DACRA peptide. The study marks the third target to emerge from iBio's partnership with AstralBio. | Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist | Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases. | Shares of IBIO traded up over 48% in the pre-market in reaction to the news. | | The $1 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.10, $1.20, $1.30 and then the pre-market high at $1.45. Beyond that, $1.62, $2 and $2.30 come into play. | Below $1, targets to the downside are $0.90, $.80 and then a gap fill at $0.7124. | | *together with Brownstone Research | | Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... | Just did a demo of what Nvidia's CEO said will be "the first multitrillion-dollar robotics industry." | Click here to watch the demoβ¦ | Because if you wait after July 23rd... | It could be too late! |
|
| | NA - Up over 170% in pre after announcing US$500 million convertible notes private placement for BNB treasury strategy | Nano Labs Ltd (NA) is a leading Web 3.0 infrastructure and product solution provider in China. | In the pre-market this morning, the company announced that it has entered into a convertible notes purchase agreement under which the Company has agreed to issue, and several investors have agreed to subscribe for, a convertible promissory notes in the aggregate principal amount of US$500 million. | The Notes will mature in 360 days following the issuance, with no interest accruing on the outstanding principal amount. During 360 days from the date of this Notes, the Notes are convertible, in whole or in part, into the Class A ordinary shares of the Company at the option of the holder thereof. The conversion price is initially US$20 per Ordinary Share, subject to adjustment as set forth in the Notes. | The Agreement marks an important step in the Company's strategic growth. As part of this initiative, Nano Labs will conduct a thorough assessment of the security and value of BNB. In the initial phase, the Company plans to acquire US$1 billion worth of BNB via convertible notes and private placements. Over the long term, Nano Labs aims to hold 5% to 10% of BNB's total circulating supply. | Shares of NA traded up over 170% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $34.73. Beyond that, $47.50, $60 and $70 come into play. | Below $34.73, targets to the downside are $30, $28, $22, $20, $18, $16 and then $12. | | MARKET NEWS π° | | | | | Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed past the MOON π. Simply text "RAGE" to 1-(888) 487-1534 π². | *Disclosure: By texting "RAGE" to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn't a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information. | | | DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). Full disclaimer: https://bullseyealerts.com/disclaimer/ | SPONSORED CONTENT & COMPENSATION: You should assume we receive compensation for any non-SV purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies ("Clients"). We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication. | CLIENT CONTENT: SV is not responsible for any content hosted on Client sites; it is the Client's responsibility to ensure compliance with applicable laws. | NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content, regardless of characterization as "educational," should be considered promotional and subject to disclosed conflicts of interest. Do NOT rely on this as personalized investment advice. SV strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS NOT TYPICAL: Past performance, testimonials, and historical results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Past newsletters, marketing materials, track records, case studies, and promotional content should NOT be relied upon as indication of future performance. Market conditions, regulatory environments, and individual circumstances vary significantly over time. Actual results will vary widely given factors such as experience, skill, risk mitigation practices, market dynamics and capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | REGULATORY STATUS: Neither SV nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | HIGH-RISK SECURITIES: Securities discussed may be penny stocks, small-cap stocks, cryptocurrencies, options, or other highly speculative investments subject to extreme price volatility, rapid and substantial price movements, limited liquidity, regulatory changes, and potential total loss of value. Market conditions can change rapidly and unpredictably. | LEGAL: In any legal action arising from or related to SV services or these terms, SV shall be entitled to recover attorneys' fees, costs, and disbursements in addition to any other relief. |
|
|
|
Tidak ada komentar:
Posting Komentar